Receptos, Revance price follow-ons

Receptos Inc. (NASDAQ:RCPT) and Revance Therapeutics Inc. (NASDAQ:RVNC) raised money in bumped-up follow-ons on Thursday. Receptos raised $178.4 million through the sale of 4.4 million shares at $40.25 in a follow-on underwritten by Credit Suisse; Leerink; BMO Capital Markets; Wedbush PacGrow; and Nomura. Receptos amended the offering to sell 3.8 million shares in the offering late Tuesday, when its share price was $38.48.

Earlier this month, Receptos said its RPC1063 met the primary endpoint in the Phase II portion of the Phase II/III RADIANCE trial to treat relapsing multiple sclerosis. RPC1063 is a selective sphingosine-1-phosphate receptor 1 ( S1PR1; S1P1; EDG1) modulator (see BioCentury Extra, June 9). ...